Anti-EGFR therapy in first-line colorectal cancer

References

• Weitz J, Koch M, Debus J, Hohler T, Galle PR, Büchler MW. Colorectal cancer. Lancet365(9454), 153–165 (2005).
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: amodel to predict long-term survival. Ann. Surg.240(4), 644–657 (2004).
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal caner. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Fehrenbacher L, Rivera F et al. Randomized Phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial (Abstract LB-2). Presented at: American Association for Cancer Research: 98th Annual Meeting. Los Angeles, CA, USA, 14–18 April 2007.
   Google Scholar
• Jonker DJ, Karapetis CS, Moore M et al. Randomized Phase III trial of cetuximab monotherapy plus best supportive care (BSC) versus BSC alone in patients with pretreated metastatic epidermal growth factor receptor (EGFR)-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [Abstract LB-1]. Presented at: American Association for Cancer Research: 98th Annual Meeting. Los Angeles, CA, USA, 14–18 April 2007.
   Google Scholar
• Vincenzi B, Santini D, Rabitti C et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer94, 792–797 (2006).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360, 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Porebska I, Harlozińska A, Bojarowski T et al. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biol.21(2), 105–115 (2000).
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol.26(10), 1626–1634 (2008).
   PubMed Web of Science ®Google Scholar
• Kohne C, Rougier P, Stroh C et al. Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO (Abstract 406). Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22–24 January 2010.
   Google Scholar
• Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: lessons from the OPUS trial. J. Clin. Oncol.29(Suppl. 4),, (2011).
   Google Scholar
• Folprecht G, Gruenberger T, Hartmann JT et al. Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CLM). Ann. Oncol.19(8), 168 (2008) (Abstract 510PD).
   PubMedGoogle Scholar
• Ciuleanu T, Nikolic V, Shmueli E et al. Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 494).
   Google Scholar
• Laurent-Puig, Cayre A, Manceau G et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J. Clin. Oncol.27(35), 5924–5930 (2009).
   PubMed Web of Science ®Google Scholar
• De Roock W, Jonker D, Di Nicolantonio F et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA304(16), 1812–1820 (2010).
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for Phase II clinical trials. Control. Clin. Trials10(1), 1–10 (1989).
   PubMedGoogle Scholar
• De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Negri FV, Bozzetti C, Lagrasta CA et al. PTEN status in advanced colorectal cancer treated with cetuximab. Br. J. Cancer102(1), 162–164 (2010).
   PubMed Web of Science ®Google Scholar
• Lamas MJ, Duran G, Balboa E et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil–oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics12(3), 433–442 (2011).
   PubMedGoogle Scholar